Ensign ENSG
- Market cap
- $10.2B
- PE
- 27.5×
- 10y median 25.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.9×
- EV/EBIT
- 21.5×
- Revenue, 12 months
- $5.5B
- +19% on a year ago
- Net margin
- 6.9%
- Free cash flow yield
- 4.1%
Ensign trades at 27.5× trailing earnings, pricier than 65% of the last ten years. Revenue was $5.5B over the last twelve months, up 19% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $940.8M+22% | $980.4M+21% | $1B+14% | $1B+13% | $1.1B+15% | $1.1B+16% | $1.2B+16% | $1.2B+19% | $1.3B+20% | $1.4B+20% | $1.4B+18% | $1.4B+17% | |
| Cost of revenue | $741.1M+23% | $781.2M−1% | $799.3M+15% | $873.6M+21% | $914.8M+23% | $897.3M+15% | $984.9M+23% | $1B+18% | $1.1B+21% | $1.1B+27% | $1.2B+18% | $1.2B+17% |
| Gross profit | $199.7M+19% | $199.2M+768% | $210.9M+11% | $162.7M−18% | $167M−16% | $235M+18% | $188.1M−11% | $198.8M+22% | $190.2M+14% | $222.3M−5% | $227.9M+21% | $239.8M+21% |
| SG&A | $51.1M+30% | $106.6M+149% | $57.2M+10% | $56.2M+5% | $56.2M+10% | $55.6M−48% | $62.6M+9% | $69.1M+23% | $67.4M+20% | $70.8M+27% | $74.2M+19% | $85.9M+24% |
| $79.8M+7% | $22.8M−70% | $82.2M+10% | $86M+10% | $89.3M+12% | $100.8M+342% | $101.4M+23% | $103.9M+21% | $96.2M+8% | $123.8M+23% | $124.9M+23% | $122.5M+18% | |
| Interest expense | $2M−4% | $2M−3% | $2M−4% | $2M+1% | $2M+0% | $2.3M+13% | $2M+4% | $2M−1% | $2M−3% | $2M−13% | $1.9M−5% | $1.9M−5% |
| Pre-tax income | $82M+13% | $31.3M−60% | $89.6M+14% | $92.1M+14% | $98.7M+20% | $105.8M+238% | $106.6M+19% | $112.4M+22% | $106.6M+8% | $130.1M+23% | $128.6M+21% | $133.7M+19% |
| $18.1M+12% | $9.5M−44% | $20.6M+12% | $20.9M+23% | $20.1M+11% | $26M+175% | $26.2M+27% | $27.9M+34% | $22.7M+13% | $34.5M+33% | $28.8M+10% | $33.8M+21% | |
| Net income | $63.9M+14% | $21.7M−64% | $68.8M+15% | $71M+11% | $78.4M+23% | $79.7M+267% | $80.3M+17% | $84.4M+19% | $83.8M+7% | $95.5M+20% | $99.7M+24% | $99.7M+18% |
| $1.11+12% | $0.38−64% | $1.19+13% | $1.22+9% | $1.34+21% | $1.36+258% | $1.37+15% | $1.44+18% | $1.42+6% | $1.61+18% | $1.67+22% | $1.68+17% | |
| 57.3M+1% | 57.6M+1% | 57.9M+1% | 58M+1% | 58.4M+2% | 58.6M+2% | 58.5M+1% | 58.6M+1% | 59M+1% | 59.3M+1% | 59.6M+2% | 59.5M+2% |
Gross profit: 65 periods, Q2 FY10 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Ensign's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ENSGEnsign | $10.2B | 27.5× | 25.5× | n/m | 1.9× | +19% | 6.9% |
| UHSUniversal Health Services | $11B | 7.6× | 13.6× | n/m | 0.6× | +10% | 8.4% |
| DVADavita | $11.7B | 15.0× | 16.1× | n/m | 0.8× | +6% | 6.0% |
| BTSGBrightSpring Health Services | $11.9B | 36.4× | 57.7× | n/m | 0.8× | +26% | 2.5% |
| EHCEncompass Health | $12.2B | 20.2× | 18.4× | n/m | 2.0× | +9% | 10.0% |
| PACSPACS | $7.5B | 27.2× | 27.2× | n/m | 1.4× | +15% | 4.8% |
| CHEChemed | $6.7B | 25.8× | 29.0× | n/m | 2.6× | +3% | 10.6% |
| SHCSotera Health | $5.2B | 31.8× | 55.4× | n/m | 4.2× | +8% | 13.4% |
| CONConcentra Group Holdings Parent | $5B | 25.5× | 17.5× | n/m | 2.2× | +14% | 8.7% |
| LFSTLifeStance Health | $4.9B | 99.5× | 142× | n/m | 3.1× | +20% | 3.2% |
| THCTenet Healthcare | $21.6B | 10.4× | 11.2× | 12.9× | 1.0× | +5% | 10.3% |
| Peer median | $9.3B | 25.6× | 22.8× | 12.9× | 1.7× | +10% | 8.6% |
Investors who own it
Investors we follow who held Ensign at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.7% of portfolioadded
More on Ensign
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .